Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer


Crinetics company announces the appointment of Tobin Schilke as chief financial officer, effective February 28, 2025.

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences


Crinetics' company management will participate in the TD Cowen 45th Annual Healthcare Conference on March 3, and the Leerink Global Healthcare Conference on March 10.

Crinetics Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit awards to 14 new non-executive employees.

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025


Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025.

Crinetics Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees.